Showing results (2441-2450 of 2,695) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|January 21, 2024
Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control studyLaura V Cooper, Tesfaye B Erbeto, Abba A Danzomo, et al.
The Lancet. Infectious Diseases|January 15, 2024
Global incidence and mortality of severe fungal diseaseDavid W Denning
The Lancet. Infectious Diseases|January 13, 2024
Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trialMaria-Jesus Pinazo, Colin Forsyth, Irene Losada, et al.
The Lancet. Infectious Diseases|January 20, 2024
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trialAchim J Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, et al.
The Lancet. Infectious Diseases|December 22, 2023
Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022Robina Aerts, Varun Mehra, Andreas H Groll, et al.
The Lancet. Infectious Diseases|March 25, 2024
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort studyMichelle Ylade, Maria Vinna Crisostomo, Jedas Veronica Daag, et al.
The Lancet. Infectious Diseases|March 25, 2024
The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experienceKogieleum Naidoo, Rubeshan Perumal, Helen Cox, et al.
The Lancet. Infectious Diseases|December 7, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trialJames Wassil, Maggie Sisti, Jeff Fairman, et al.
The Lancet. Infectious Diseases|November 13, 2023
Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational studyIvan Barilar, Tatiana Fernando, Christian Utpatel, et al.
The Lancet. Infectious Diseases|November 10, 2023
Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trialViviane P Sprecher, Daniela Hofmann, Vanthanom Savathdy, et al.
Pageof 270